with adverse events consistent with the known effects of targeting the renin-angiotensin-aldosterone system -- an increased risk of hyperkalemia and hyponatremia and decreases in the eGFR ...

a Estimated cost, based on average wholesale price (Drug Topics Red Book, 1999), to the pharmacist for a one-month supply at the usual starting dosage.